Farxiga-话题@MedSci

#Farxiga#

12篇内容 | 1570人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1257543, encodeId=d147125e543ef, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, objectTitle=阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点, objectType=article, longId=726470, objectId=5a4ce2647008, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a4ce2647008, replyNumber=0, likeNumber=83, createdTime=2022-05-11, rootId=0, userName=mhzhuang@stu.e, userId=416347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a4ce2647008, moduleTitle=阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a4ce2647008)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257542, encodeId=c99d125e542c2, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, objectTitle=Farxiga（达格列净）将肾衰竭、心血管或肾脏死亡风险降低39％, objectType=article, longId=200077, objectId=0d5f2000e754, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d5f2000e754, replyNumber=0, likeNumber=55, createdTime=2020-09-02, rootId=0, userName=mhzhuang@stu.e, userId=416347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d5f2000e754, moduleTitle=Farxiga（达格列净）将肾衰竭、心血管或肾脏死亡风险降低39％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d5f2000e754)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257541, encodeId=4392125e541ab, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, objectTitle=SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险, objectType=article, longId=197735, objectId=bb3a19e7357e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb3a19e7357e, replyNumber=0, likeNumber=59, createdTime=2020-07-20, rootId=0, userName=mhzhuang@stu.e, userId=416347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb3a19e7357e, moduleTitle=SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb3a19e7357e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257540, encodeId=08e0125e540a0, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, objectTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, objectType=article, longId=195939, objectId=e40a195939e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e40a195939e1, replyNumber=0, likeNumber=73, createdTime=2020-06-17, rootId=0, userName=mhzhuang@stu.e, userId=416347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e40a195939e1, moduleTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e40a195939e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257539, encodeId=67e2125e539a1, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, objectTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, objectType=article, longId=193624, objectId=acac19362471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acac19362471, replyNumber=0, likeNumber=72, createdTime=2020-05-08, rootId=0, userName=mhzhuang@stu.e, userId=416347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acac19362471, moduleTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acac19362471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257538, encodeId=ec44125e5385f, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, objectTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, objectType=article, longId=185842, objectId=eae01858423e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae01858423e, replyNumber=0, likeNumber=66, createdTime=2020-01-08, rootId=0, userName=mhzhuang@stu.e, userId=416347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae01858423e, moduleTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae01858423e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257537, encodeId=443f125e53700, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, objectTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, objectType=article, longId=183195, objectId=6133183195fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6133183195fa, replyNumber=0, likeNumber=72, createdTime=2019-11-20, rootId=0, userName=mhzhuang@stu.e, userId=416347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6133183195fa, moduleTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6133183195fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257536, encodeId=61b7125e53632, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, objectTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, objectType=article, longId=181704, objectId=6557181e048a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6557181e048a, replyNumber=0, likeNumber=66, createdTime=2019-10-23, rootId=0, userName=mhzhuang@stu.e, userId=416347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6557181e048a, moduleTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6557181e048a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257535, encodeId=9364125e5351e, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, objectTitle=2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功, objectType=article, longId=178689, objectId=11b21e8689cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11b21e8689cf, replyNumber=0, likeNumber=74, createdTime=2019-09-04, rootId=0, userName=mhzhuang@stu.e, userId=416347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11b21e8689cf, moduleTitle=2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11b21e8689cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257534, encodeId=5d76125e53403, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, objectTitle=FDA拒绝批准阿斯利康的Farxiga治疗1型糖尿病, objectType=article, longId=175551, objectId=4df31e555160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4df31e555160, replyNumber=0, likeNumber=95, createdTime=2019-07-17, rootId=0, userName=mhzhuang@stu.e, userId=416347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4df31e555160, moduleTitle=FDA拒绝批准阿斯利康的Farxiga治疗1型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4df31e555160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257533, encodeId=7463125e53354, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, objectTitle=控糖不再伤“心”丨糖尿病新药Farxiga可降低心衰风险, objectType=article, longId=154041, objectId=e56615404196, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e56615404196, replyNumber=0, likeNumber=58, createdTime=2018-11-22, rootId=0, userName=mhzhuang@stu.e, userId=416347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e56615404196, moduleTitle=控糖不再伤“心”丨糖尿病新药Farxiga可降低心衰风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e56615404196)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1257532, encodeId=eaad125e5320c, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, objectTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, objectType=article, longId=149631, objectId=33901496318e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33901496318e, replyNumber=0, likeNumber=48, createdTime=2018-09-27, rootId=0, userName=mhzhuang@stu.e, userId=416347, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33901496318e, moduleTitle=III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33901496318e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Farxiga

2020-05-29

mhzhuang@stu.e (审核中...)

前往app查看评论内容

#Farxiga#

阿斯利康表示Farxiga达到了III期心力衰竭研究的主要终点

2022-05-11

mhzhuang@stu.e (审核中...)

前往app查看评论内容

#Farxiga#

Farxiga（达格列净）将肾衰竭、心血管或肾脏死亡风险降低39％

2020-09-02

mhzhuang@stu.e (审核中...)

前往app查看评论内容

#Farxiga#

SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险

2020-07-20

mhzhuang@stu.e (审核中...)

前往app查看评论内容

#Farxiga#

ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险

2020-06-17

mhzhuang@stu.e (审核中...)

前往app查看评论内容

#Farxiga#

FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者

2020-05-08

mhzhuang@stu.e (审核中...)

前往app查看评论内容

#Farxiga#

阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查

2020-01-08

mhzhuang@stu.e (审核中...)

前往app查看评论内容

#Farxiga#

2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善

2019-11-20

mhzhuang@stu.e (审核中...)

前往app查看评论内容

#Farxiga#

阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险

2019-10-23

mhzhuang@stu.e (审核中...)

前往app查看评论内容

#Farxiga#

2019欧洲心脏病学会ESC：阿斯利康的糖尿病药物Farxiga治疗心力衰竭的III期临床大获成功

2019-09-04

mhzhuang@stu.e (审核中...)

前往app查看评论内容

#Farxiga#

FDA拒绝批准阿斯利康的Farxiga治疗1型糖尿病

2019-07-17

mhzhuang@stu.e (审核中...)

前往app查看评论内容

#Farxiga#

控糖不再伤“心”丨糖尿病新药Farxiga可降低心衰风险

2018-11-22

mhzhuang@stu.e (审核中...)

前往app查看评论内容

#Farxiga#

III期临床试验显示：阿斯利康SCLT2抑制剂Farxiga显着降低II型糖尿病患者的心力衰竭和心血管死亡住院治疗率

2018-09-27

科室
- - 订阅+
  - 更多科室
工具
服务